EP0385663A3 - Cycloalcanes hétérocycliques comme inhibiteurs de 5-lypoxygénase - Google Patents

Cycloalcanes hétérocycliques comme inhibiteurs de 5-lypoxygénase Download PDF

Info

Publication number
EP0385663A3
EP0385663A3 EP19900301935 EP90301935A EP0385663A3 EP 0385663 A3 EP0385663 A3 EP 0385663A3 EP 19900301935 EP19900301935 EP 19900301935 EP 90301935 A EP90301935 A EP 90301935A EP 0385663 A3 EP0385663 A3 EP 0385663A3
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
ring
alkylene
lipoxygenase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19900301935
Other languages
German (de)
English (en)
Other versions
EP0385663B1 (fr
EP0385663A2 (fr
Inventor
Graham Charles Crawley
Jean-Marc Marie Maurice Girodeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Syngenta Ltd
Original Assignee
ICI Pharma SA
Zeneca Pharma SA
Zeneca Ltd
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICI Pharma SA, Zeneca Pharma SA, Zeneca Ltd, Imperial Chemical Industries Ltd filed Critical ICI Pharma SA
Publication of EP0385663A2 publication Critical patent/EP0385663A2/fr
Publication of EP0385663A3 publication Critical patent/EP0385663A3/fr
Application granted granted Critical
Publication of EP0385663B1 publication Critical patent/EP0385663B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Buildings Adapted To Withstand Abnormal External Influences (AREA)
  • Optical Communication System (AREA)
  • Electroluminescent Light Sources (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP90301935A 1989-02-28 1990-02-22 Cycloalcanes hétérocycliques comme inhibiteurs de 5-lypoxygénase Expired - Lifetime EP0385663B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP89400559 1989-02-28
EP89400559 1989-02-28

Publications (3)

Publication Number Publication Date
EP0385663A2 EP0385663A2 (fr) 1990-09-05
EP0385663A3 true EP0385663A3 (fr) 1991-11-21
EP0385663B1 EP0385663B1 (fr) 1995-12-06

Family

ID=8202930

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90301935A Expired - Lifetime EP0385663B1 (fr) 1989-02-28 1990-02-22 Cycloalcanes hétérocycliques comme inhibiteurs de 5-lypoxygénase

Country Status (15)

Country Link
EP (1) EP0385663B1 (fr)
JP (1) JP2851353B2 (fr)
AT (1) ATE131158T1 (fr)
AU (1) AU626989B2 (fr)
CA (1) CA2010211A1 (fr)
DE (1) DE69023940T2 (fr)
DK (1) DK0385663T3 (fr)
ES (1) ES2080788T3 (fr)
FI (1) FI901009A0 (fr)
GR (1) GR3018316T3 (fr)
IL (1) IL93343A0 (fr)
NO (1) NO900917L (fr)
NZ (1) NZ232514A (fr)
PT (1) PT93288A (fr)
ZA (1) ZA901042B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
IE911919A1 (en) * 1990-06-21 1992-01-01 Zeneca Ltd Bicyclic heterocyclic compounds
US5227399A (en) * 1991-02-28 1993-07-13 Merck Frosst Canada, Inc. Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis
US5281720A (en) * 1991-02-28 1994-01-25 Merck Frosst Canada, Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
EP0505122A1 (fr) * 1991-03-21 1992-09-23 Zeneca Limited Dérivés alpha, alpha-dialkylbenzyle
EP0570112A1 (fr) * 1992-04-23 1993-11-18 Zeneca Limited Dérivés de cycloalcanes
US5308852A (en) * 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US5268379A (en) * 1992-08-24 1993-12-07 Abbott Laboratories Ether-containing inhibitors of 5-lipoxygenase
US5426109A (en) * 1992-08-27 1995-06-20 Merck Frosst Canada, Inc. Phenylnaphthalene hydroxy acids
US5428060A (en) * 1992-08-27 1995-06-27 Merck Frosst Canada, Inc. Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis
US5252599A (en) * 1992-08-27 1993-10-12 Merck Frosst Canada, Inc. Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
US5350744A (en) * 1992-08-27 1994-09-27 Merck Frosst Canada, Inc. Phenylnaphthalene lactones as inhibitors of leukotriene biosynthesis
WO1994005638A1 (fr) * 1992-09-02 1994-03-17 Abbott Laboratories Composes de trans 1,4-diethercyclohexane utilises en tant qu'inhibiteurs de la 5-lipoxygenase
US5446062A (en) * 1993-11-12 1995-08-29 Abbott Laboratories ((4-alkoxypyran-4-yl) substituted) ether, arylalkyl-, arylalkenyl-, and arylalkynyl)urea inhibitors of 5-lipoxygenase
US5407959A (en) * 1993-11-12 1995-04-18 Abbott Laboratories (Trans-1,4-dialkoxycyclohexyl) substituted arylalkylaryl-arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6548670B1 (en) 2001-07-19 2003-04-15 Air Products And Chemicals, Inc. Methods for preparing 5- and 6-benzyl-functionalized quinoxalines
US6825221B2 (en) 2001-10-18 2004-11-30 Allergan, Inc. Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
EP1978966A4 (fr) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc Inhibiteurs tricycliques de la 5-lipoxygenase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181568A2 (fr) * 1984-10-30 1986-05-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Composés anti-inflammatoires/antiallergiques
EP0200101A2 (fr) * 1985-04-16 1986-11-05 Usv Pharmaceutical Corporation Ethers aryliques et hétéroaryliques comme agents pour le traitement de maladies de l'hypersensibilité
US4661596A (en) * 1985-02-21 1987-04-28 American Home Products Corporation Quinolinyl (or pyridinyl) methoxy substituted naphthalene compounds as antiallergic agents
EP0224086A2 (fr) * 1985-11-16 1987-06-03 Bayer Ag Ethers benzyles substitués

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66512B1 (en) * 1989-02-28 1996-01-10 Ici Plc Heterocyclic ethers as 5-lipoxygenase inhibitors
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
IL93344A0 (en) * 1989-02-28 1990-11-29 Ici Plc Heterocyclic cyclic ethers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181568A2 (fr) * 1984-10-30 1986-05-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Composés anti-inflammatoires/antiallergiques
US4661596A (en) * 1985-02-21 1987-04-28 American Home Products Corporation Quinolinyl (or pyridinyl) methoxy substituted naphthalene compounds as antiallergic agents
EP0200101A2 (fr) * 1985-04-16 1986-11-05 Usv Pharmaceutical Corporation Ethers aryliques et hétéroaryliques comme agents pour le traitement de maladies de l'hypersensibilité
EP0224086A2 (fr) * 1985-11-16 1987-06-03 Bayer Ag Ethers benzyles substitués

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, no. 1, January 1987, pages 96-104, American Chemical Society, Columbus, Ohio, US; J.H. MUSSER et al.: "Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists" *

Also Published As

Publication number Publication date
NZ232514A (en) 1992-04-28
ES2080788T3 (es) 1996-02-16
JP2851353B2 (ja) 1999-01-27
PT93288A (pt) 1990-08-31
DE69023940D1 (de) 1996-01-18
DK0385663T3 (da) 1996-03-11
JPH02268158A (ja) 1990-11-01
NO900917L (no) 1990-08-29
FI901009A0 (fi) 1990-02-28
GR3018316T3 (en) 1996-03-31
IL93343A0 (en) 1990-11-29
AU626989B2 (en) 1992-08-13
DE69023940T2 (de) 1996-04-25
EP0385663B1 (fr) 1995-12-06
ATE131158T1 (de) 1995-12-15
ZA901042B (en) 1990-10-31
CA2010211A1 (fr) 1990-08-31
NO900917D0 (no) 1990-02-27
AU4976490A (en) 1990-09-06
EP0385663A2 (fr) 1990-09-05

Similar Documents

Publication Publication Date Title
AU627275B2 (en) Heterocycles
AU626989B2 (en) Heterocyclic cycloalkanes
EP0420511A3 (en) Heterocyclic derivatives
AU3801489A (en) Thiazole derivatives as 5-lipoxygenase inhibitors
AU626988B2 (en) Heterocyclic cyclic ethers
AU4713489A (en) Cycloalkane derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19911130

17Q First examination report despatched

Effective date: 19930827

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZENECA PHARMA S.A.

Owner name: ZENECA LIMITED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 131158

Country of ref document: AT

Date of ref document: 19951215

Kind code of ref document: T

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19951229

Year of fee payment: 7

REF Corresponds to:

Ref document number: 69023940

Country of ref document: DE

Date of ref document: 19960118

ITF It: translation for a ep patent filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19960207

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19960213

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19960215

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2080788

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19960227

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19960229

Year of fee payment: 7

Ref country code: LU

Payment date: 19960229

Year of fee payment: 7

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3018316

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19960412

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970222

Ref country code: DK

Effective date: 19970222

Ref country code: AT

Effective date: 19970222

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19970223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19970228

BERE Be: lapsed

Owner name: S.A. ZENECA PHARMA

Effective date: 19970228

Owner name: ZENECA LTD

Effective date: 19970228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19970831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19970901

REG Reference to a national code

Ref country code: GR

Ref legal event code: MM2A

Free format text: 3018316

EUG Se: european patent has lapsed

Ref document number: 90301935.4

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19970901

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19990209

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19990225

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19990301

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19990310

Year of fee payment: 10

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 19990405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000229

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000229

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000222

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050222